Zoetis Inc.
NYQ: ZTSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Zoetis Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ZTS Z-Score →About Zoetis Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
📊 Fundamental Analysis
Zoetis Inc. demonstrates exceptional profitability, with a profit margin of 28.2%.
The company recently reported 3.0% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is 66.0%, which reflects exceptional capital efficiency.
At a current price of $117.86, ZTS currently trades near the bottom of its 52-week range (8%), indicating potential value or weakness (Range: $113.29 - $172.23).
💰 Valuation Insight
ZTS is valued broadly in line with the sector at a PE of 19.58. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
✅
Return on Equity
Excellent
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$49.75B
Trailing P/E
19.58
Forward P/E
15.61
Beta (5Y)
0.97
52W High
$172.23
52W Low
$113.29
Avg Volume
4.27M
Day High
Day Low